Dear All, As we\’ve discussed previously (1 Oct 2024 newsletter), the HLM on AMR at UNGA 2024 is but one stop along the road to global action on AMR (acronymics: HLM on AMR at UNGA 2024 = High-Level Meeting on AMR at the 2024 UN General Assembly). In follow-up, we now have two AMR-related declarations from
Dear All, The Global Leaders Group on Antimicrobial Resistance (GLG AMR) chaired by Her Excellency Prime Minister Mia Amor Mottley of Barbados is putting out a call for more members! Founded in 2020 by the Quadripartite, the GLG AMR has been fundamental to steady build of global awareness about AMR at senior political levels. One example of their impact
Dear All, MyCARE, a fungal patient advocacy organization, and the Partnership to Fight Infectious Diseases (PFID), are sending a letter to the California Congressional Delegation asking them to weigh in U.S. House and Senate leadership to pass the PASTEUR Act by the end of the year. The state of California has the largest Congressional delegation and
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Post-newsletter addendum: A slide deck that summarizes the data from the paper is now available. We talked in a 22 Mar 2021 newsletter about ensuring access to new antibiotics and you should take a moment to refresh your memory of its discussions of
Dear All, Anthony McDonnell and his colleagues at CGD (Center for Global Development) have just released a truly lovely paper on the economics of antibiotic resistance. What makes this one special is that the paper dissects the problem of AMR through an economist’s spectacles in a way that is very accessible to the non-expert. You
Dear All, A new paper from Anthony McDonnell and a team led by the Center for Global Development extends estimates of the health-related impact of AMR (e.g., death) to a consideration of the economic ($) cost of AMR. To follow the plot, here are the links you will need: The new paper: “Forecasting the Fallout
Dear All, BARDA has released a fascinating Sources Sought Notice (SSN) seeking data on antibacterials near, at, or beyond Phase 2. I’ve never seen one before, but an SSN is market research with which BARDA will “collect feedback from current and prospective antibiotic development partners” that will “serve as continued market research for potential future acquisitions
Dear All, Four big reports have recently been released and are very much worth reviewing. First, the Global AMR R&D Hub and the WHO AMR Team have written a report entitled “Incentivising the development of new antibacterial treatments“. This report is a response to a 2021 request by the G7 Finance Ministers for a report on
Aside: Please refer to our UNGA 2024 webpage for additional post-HLM notes and updates. 28 Oct 2024 addendum and another way to get a view of the day: Hosted by Cesar Arias, Editor-in-Chief of Antimicrobial Agents and Therapy, John and Prabha Fernandes recorded a podcast discussion of the HLM. Dear All (and with thanks to Damiano
Dear All (and with thanks to Damiano for co-authoring), We have exciting news from the G7 Health Ministers’ Meeting, which was held in person in Ancona on 9-11 October 2024, and the accompanying G7 Joint Finance and Health Ministers’ Meeting, which took place in a hybrid format on 10 October 2024. At the press conference closing